The first formal human cardiac safety study of Firdapse (amifampridine phosphate) met its pre-specified endpoint, demonstrating no effect on heart rate or cardiac depolarization when administered at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback